Immunotherapy News and Research

Latest Immunotherapy News and Research

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

Celldex Therapeutics, Inc. today announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers.

13 Dec 2009

Zevalin clinical data presented at 2009 ASH meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the 51st Annual Meeting of the American Society of Hematology (ASH), which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

11 Dec 2009

HST Global and HMD team up to develop curriculum for FIT protocol

HST Global, Inc. (OTCBB: HSTC) today announced a Partnership with Dr. James W. Forsythe to facilitate the development of a curriculum for the licensing and/or certification to administer Dr. Forsythe’s immune therapy in clinics to be built or acquired by HST Global, Inc.

11 Dec 2009

Promising trial on immunotherapy for preventing childhood cancer recurrence

CHILDREN in the UK with a high risk form of the childhood cancer neuroblastoma are set to benefit from a new international clinical trial - funded by Cancer Research UK - which uses immunotherapy to help prevent the disease from coming back.

10 Dec 2009

Genetic variations in Sonic Hedgehog pathway associated with response to standard immunotherapy

Genetic variations in the Sonic Hedgehog pathway increase the likelihood of recurrence, reduce survival time and limit response to therapy for people with non-muscle invasive bladder cancer, scientists from The University of Texas M. D. Anderson Cancer Center reported today at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

10 Dec 2009

Memgen announces positive clinical data of ISF35 with chemotherapy

Memgen announced today that positive data evaluating its active cellular immunotherapy product, ISF35, in combination with chemotherapy in resistant chronic lymphocytic leukemia (CLL) were presented December 7 during the 51st Annual Meeting of the American Society of Hematology (Abstract #376).

9 Dec 2009

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Neovacs, a biotechnology company developing proprietary immunotherapies for autoimmune and chronic diseases, today announced the initiation of a Phase IIa clinical study of its TNFα Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFα monoclonal antibody and who test positive for anti-drug antibodies (ADAs).

8 Dec 2009

Celldex Therapeutics to present poster on its first antibody-drug conjugate product

Celldex Therapeutics, Inc. today announced that the Company’s first antibody-drug conjugate (ADC) product candidate, CDX-011 (formerly CR011-vcMMAE), for the treatment of locally advanced or metastatic breast cancer will be the subject of a poster presentation at the 2009 San Antonio Breast Cancer Symposium.

8 Dec 2009

Researchers explore optimal induction therapies for managing blood cancer

There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in order to discover new treatment options and provide patients with the best care.

7 Dec 2009

Results from Phase III pivotal study of FIRMAGON presented

Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III pivotal study of FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in prostate cancer patients during the first year of treatment.

4 Dec 2009

DCVax therapeutic cancer vaccine manufacturing process receives patent approval

Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") announced today that the US Patent and Trademark Office has allowed its patent application on a system for automation of the initial stages of the manufacture of the Company's DCVax® therapeutic cancer vaccines.

4 Dec 2009

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center relating to an immunotherapy targeting cancer stem cells (CSCs) which has demonstrated in pre-clinical animal models significant abilities to target and destroy CSCs.

3 Dec 2009

Protein marker may hold the key against pancreatic cancer

Pancreatic tumors can be identified by a readily detectable marker that shows promise as a basis for immune therapy against the disease, according to research at Washington University School of Medicine in St. Louis.

2 Dec 2009

Infections remain a common problem in ICU patients

An international study that examined the extent of infections in nearly 1,300 intensive care units (ICUs) in 75 countries found that about 50 percent of the patients were considered infected, with infection associated with an increased risk of death in the hospital, according to a study in the December 2 issue of JAMA.

2 Dec 2009

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

Memgen announced today that results from its ongoing, Leukemia & Lymphoma Society co-sponsored clinical trial in chronic lymphocytic leukemia (CLL) have been selected for an oral presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

2 Dec 2009

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -produced from healthy and tumour cells from the patient him or herself- and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

1 Dec 2009

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

Stallergenes granted European approval to market Oralair

Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure. Germany, the first country where Oralair(R) has been marketed, was the reference Member state.

27 Nov 2009

MUHC's innovative treatment for HIV patients passes first clinical trial successfully

An innovative treatment for HIV patients developed by McGill University Health Centre researchers has passed its first clinical trial with flying colours. The new approach is an immunotherapy customized for each individual patient, and was developed by Dr. J-P. Routy from the Research Institute of the MUHC in collaboration with Dr. R. S-kaly from the Universit- de Montr-al.

26 Nov 2009

Fred Hutchinson Cancer Research Center receives $10 million to advance biomedical research

Fred Hutchinson Cancer Research Center has received a pledge of $10 million to advance the promising field of immunotherapy research to treat and cure cancer, even in late stages.

23 Nov 2009

Immunotherapy News and Research

Latest Immunotherapy News and Research

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

Zevalin clinical data presented at 2009 ASH meeting

HST Global and HMD team up to develop curriculum for FIT protocol

Promising trial on immunotherapy for preventing childhood cancer recurrence

Genetic variations in Sonic Hedgehog pathway associated with response to standard immunotherapy

Memgen announces positive clinical data of ISF35 with chemotherapy

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Celldex Therapeutics to present poster on its first antibody-drug conjugate product

Researchers explore optimal induction therapies for managing blood cancer

Results from Phase III pivotal study of FIRMAGON presented

DCVax therapeutic cancer vaccine manufacturing process receives patent approval

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

Protein marker may hold the key against pancreatic cancer

Infections remain a common problem in ICU patients

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

Clinical trials of personalised vaccines to fight glioblastomas

Stallergenes granted European approval to market Oralair

MUHC's innovative treatment for HIV patients passes first clinical trial successfully

Fred Hutchinson Cancer Research Center receives $10 million to advance biomedical research

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Immunotherapy News and Research

Latest Immunotherapy News and Research

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in